![Banseog [ biohealth ]](/assets/brand/banseog-biohealth-on-dark.svg?v=20261015){kind=small}
A global CDMO working with biologics innovators ranging from biotech start-ups to large pharmaceutical companies.
A 120,000-liter antibody manufacturing plant in Songdo, Incheon, equipped with eight 15,000-liter stainless-steel bioreactors. Construction was completed and approval for use obtained in June 2026; commissioning and production-system validation begin in the second half of 2026.
A commercial manufacturing facility in Syracuse, New York, with more than 30 years of clinical and commercial biologics manufacturing experience. It provides antibody drug-substance manufacturing and integrated bioconjugate manufacturing from antibody production through conjugation at a single site.
The company's ADC (antibody-drug conjugate) platform; research results produced jointly with Kanaph Therapeutics were presented at AACR in April 2026.
Expanded its antibody manufacturing agreement with Ottimo Pharma, adding commercial process development and characterization to the scope of the June 2025 agreement; the work is handled by the development team at Syracuse Bio Campus.
Completed construction of Songdo Bio Campus Plant 1 (120,000 liters) and obtained approval for use, about two years after construction began in 2024.
Entered a long-term strategic manufacturing partnership with Alvotech to produce drug substance for multiple antibody biosimilars at the Syracuse facility; commercial supply depends on technology transfer, manufacturing qualification and regulatory approvals.
Individual vacancy
Observed 2026-10-25 · Application window Date unconfirmed — 2026-11-02
Individual vacancy
Observed 2026-10-25 · Application window Date unconfirmed — 2026-11-02
A brief based on selected official material, not an exhaustive product or vacancy list.